Alkermes stock price target raised to $46 from $42 at UBS on NT2 study
PositiveFinancial Markets

Alkermes has received a boost as UBS raised its stock price target from $42 to $46 following promising results from the NT2 study. This adjustment reflects growing confidence in the company's potential and the effectiveness of its treatments, which could lead to increased investor interest and market performance. Such developments are crucial for Alkermes as they navigate the competitive pharmaceutical landscape.
— Curated by the World Pulse Now AI Editorial System